Foresite Capital Management II, LLC Activity Q4 2014-Q3 2023

Q2 2023

			Value		Shares		↓ Weighting
TXG	New	10x Genomics, Inc.	$39,564,204	–	708,528	–	100.00%	–

Q4 2022

			Value		Shares		↓ Weighting
TXG	Exit	10x Genomics, Inc.	$0	–	-1,753,528	–	-100.00%	–

Q2 2022

			Value		Shares		↓ Weighting
TXG	New	10x Genomics, Inc.	$79,347,000	–	1,753,528	–	100.00%	–

Q4 2021

			Value		Shares		↓ Weighting
EPZM	Exit	Epizyme, Inc.	$0	–	-832,336	–	-1.52%	–
XLRN	Exit	Acceleron Pharma Inc.	$0	–	-45,884	–	-2.81%	–
NVAX	Exit	Novavax, Inc.	$0	–	-67,373	–	-4.96%	–
TXG	Exit	10x Genomics, Inc.	$0	–	-1,753,528	–	-90.72%	–

Q3 2021

			Value		Shares		↓ Weighting
EPZM	Sell	Epizyme, Inc.	$4,262,000	-48.7%	832,336	-16.8%	1.52%	-32.2%

Q2 2021

			Value		Shares		↓ Weighting
TXG	New	10x Genomics, Inc.	$343,376,000	–	1,753,528	–	92.37%	–
NVAX	New	Novavax, Inc.	$14,304,000	–	67,373	–	3.85%	–
EPZM	New	Epizyme, Inc.	$8,310,000	–	1,000,002	–	2.24%	–
XLRN	New	Acceleron Pharma Inc.	$5,758,000	–	45,884	–	1.55%	–

Q4 2020

			Value		Shares		↓ Weighting
XLRN	Exit	Acceleron Pharma Inc.	$0	–	-45,884	–	-1.12%	–
NVAX	Exit	Novavax, Inc.	$0	–	-67,373	–	-1.59%	–
EPZM	Exit	Epizyme, Inc.	$0	–	-862,402	–	-2.24%	–
TXG	Exit	10x Genomics, Inc.	$0	–	-3,503,528	–	-95.05%	–

Q3 2020

			Value		Shares		↓ Weighting
TXG	Sell	10x Genomics, Inc.	$436,820,000	-11.1%	3,503,528	-36.3%	95.05%	-1.6%
NVAX	New	Novavax, Inc.	$7,300,000	–	67,373	–	1.59%	–
XLRN	Buy	Acceleron Pharma Inc.	$5,163,000	+55.8%	45,884	+31.9%	1.12%	+72.5%

Q2 2020

			Value		Shares		↓ Weighting
TXG	New	10x Genomics, Inc.	$491,520,000	–	5,503,528	–	96.63%	–
EPZM	New	Epizyme, Inc.	$13,850,000	–	862,402	–	2.72%	–
XLRN	New	Acceleron Pharma Inc.	$3,314,000	–	34,784	–	0.65%	–

Q4 2019

			Value		Shares		↓ Weighting
ALDR	Exit	Alder BioPharmaceuticals, Inc.	$0	–	-146,800	–	-0.58%	–
XLRN	Exit	Acceleron Pharma Inc.	$0	–	-188,602	–	-1.58%	–
EPZM	Exit	Epizyme, Inc.	$0	–	-1,488,444	–	-3.25%	–
INSM	Exit	Insmed Incorporated	$0	–	-915,016	–	-3.41%	–
AERI	Exit	Aerie Pharmaceuticals, Inc.	$0	–	-1,672,714	–	-6.80%	–
AIMT	Exit	Aimmune Therapeutics, Inc.	$0	–	-2,605,499	–	-11.53%	–
TXG	Exit	10x Genomics, Inc.	$0	–	-6,837,253	–	-72.85%	–

Q3 2019

			Value		Shares		↓ Weighting
TXG	New	10x Genomics, Inc.	$344,598,000	–	6,837,253	–	72.85%	–
AIMT	Sell	Aimmune Therapeutics, Inc.	$54,559,000	-3.9%	2,605,499	-4.4%	11.53%	-63.9%
INSM	Sell	Insmed Incorporated	$16,141,000	-34.0%	915,016	-4.2%	3.41%	-75.2%
ALDR	Sell	Alder BioPharmaceuticals, Inc.	$2,769,000	-85.2%	146,800	-90.7%	0.58%	-94.4%
TWST	Exit	Twist Bioscience Corporation	$0	–	-72,849	–	-1.19%	–

Q2 2019

			Value		Shares		↓ Weighting
AIMT	New	Aimmune Therapeutics, Inc.	$56,767,000	–	2,726,568	–	31.92%	–
AERI	New	Aerie Pharmaceuticals, Inc.	$49,429,000	–	1,672,714	–	27.79%	–
INSM	New	Insmed Incorporated	$24,460,000	–	955,462	–	13.75%	–
EPZM	New	Epizyme, Inc.	$18,680,000	–	1,488,444	–	10.50%	–
ALDR	New	Alder BioPharmaceuticals, Inc.	$18,670,000	–	1,586,220	–	10.50%	–
XLRN	New	Acceleron Pharma Inc.	$7,748,000	–	188,602	–	4.36%	–
TWST	New	Twist Bioscience Corporation	$2,113,000	–	72,849	–	1.19%	–

Q4 2018

			Value		Shares		↓ Weighting
SGMO	Exit	Sangamo Therapeutics, Inc.	$0	–	-80,500	–	-0.50%	–
BDSI	Exit	BioDelivery Sciences International, Inc.	$0	–	-949,233	–	-0.98%	–
DNLI	Exit	Denali Therapeutics Inc.	$0	–	-250,000	–	-2.01%	–
ADAP	Exit	Adaptimmune Therapeutics PLCsponds adr	$0	–	-500,000	–	-2.51%	–
XLRN	Exit	Acceleron Pharma Inc.	$0	–	-220,268	–	-4.66%	–
EPZM	Exit	Epizyme, Inc.	$0	–	-1,432,364	–	-5.62%	–
INSM	Exit	Insmed Incorporated	$0	–	-967,636	–	-7.24%	–
ALDR	Exit	Alder BioPharmaceuticals, Inc.	$0	–	-1,586,220	–	-9.77%	–
AIMT	Exit	Aimmune Therapeutics, Inc.	$0	–	-3,300,797	–	-33.32%	–
AERI	Exit	Aerie Pharmaceuticals, Inc.	$0	–	-1,464,749	–	-33.37%	–

Q3 2018

			Value		Shares		↓ Weighting
AIMT	Sell	Aimmune Therapeutics, Inc.	$90,046,000	-0.2%	3,300,797	-1.7%	33.32%	+4.8%
ALDR	Sell	Alder BioPharmaceuticals, Inc.	$26,411,000	-0.9%	1,586,220	-5.9%	9.77%	+4.1%
EPZM	Sell	Epizyme, Inc.	$15,183,000	-23.7%	1,432,364	-2.4%	5.62%	-19.8%
XLRN	Sell	Acceleron Pharma Inc.	$12,606,000	+6.1%	220,268	-10.0%	4.66%	+11.5%
ADAP	Sell	Adaptimmune Therapeutics PLCsponds adr	$6,780,000	-18.4%	500,000	-28.6%	2.51%	-14.3%
BDSI	Buy	BioDelivery Sciences International, Inc.	$2,658,000	+2853.3%	949,233	+3012.2%	0.98%	+2975.0%

Q2 2018

			Value		Shares		↓ Weighting
AERI	New	Aerie Pharmaceuticals, Inc.	$98,944,000	–	1,464,749	–	34.86%	–
AIMT	New	Aimmune Therapeutics, Inc.	$90,263,000	–	3,356,749	–	31.80%	–
ALDR	New	Alder BioPharmaceuticals, Inc.	$26,642,000	–	1,686,220	–	9.39%	–
INSM	New	Insmed Incorporated	$22,885,000	–	967,636	–	8.06%	–
EPZM	New	Epizyme, Inc.	$19,894,000	–	1,468,215	–	7.01%	–
XLRN	New	Acceleron Pharma Inc.	$11,876,000	–	244,756	–	4.18%	–
ADAP	New	Adaptimmune Therapeutics PLCsponds adr	$8,309,000	–	700,000	–	2.93%	–
DNLI	New	Denali Therapeutics Inc.	$3,813,000	–	250,000	–	1.34%	–
SGMO	New	Sangamo Therapeutics, Inc.	$1,143,000	–	80,500	–	0.40%	–
BDSI	New	BioDelivery Sciences International, Inc.	$90,000	–	30,500	–	0.03%	–

Q4 2017

			Value		Shares		↓ Weighting
ZFGN	Exit	Zafgen, Inc.	$0	–	-30,775	–	-0.04%	–
OREXQ	Exit	Orexigen Therapeutics, Inc.	$0	–	-523,132	–	-0.45%	–
LOXO	Exit	Loxo Oncology, Inc.	$0	–	-14,300	–	-0.53%	–
DERM	Exit	Dermira, Inc.	$0	–	-58,624	–	-0.64%	–
JNCE	Exit	Jounce Therapeutics, Inc.	$0	–	-119,912	–	-0.76%	–
JUNO	Exit	Juno Therapeutics, Inc.	$0	–	-90,000	–	-1.64%	–
XLRN	Exit	Acceleron Pharma Inc.	$0	–	-244,756	–	-3.70%	–
INSM	Exit	Insmed Incorporated	$0	–	-300,000	–	-3.80%	–
ALDR	Exit	Alder BioPharmaceuticals, Inc.	$0	–	-1,043,832	–	-5.18%	–
EPZM	Exit	Epizyme, Inc.	$0	–	-1,543,108	–	-11.92%	–
AERI	Exit	Aerie Pharmaceuticals, Inc.	$0	–	-1,672,714	–	-32.95%	–
AIMT	Exit	Aimmune Therapeutics, Inc.	$0	–	-3,820,462	–	-38.39%	–

Q3 2017

			Value		Shares		↓ Weighting
AIMT	Sell	Aimmune Therapeutics, Inc.	$94,709,000	+15.4%	3,820,462	-4.3%	38.39%	+2.1%
EPZM	Buy	Epizyme, Inc.	$29,396,000	+31.1%	1,543,108	+3.9%	11.92%	+16.0%
INSM	New	Insmed Incorporated	$9,363,000	–	300,000	–	3.80%	–
XLRN	New	Acceleron Pharma Inc.	$9,134,000	–	244,756	–	3.70%	–
JUNO	New	Juno Therapeutics, Inc.	$4,037,000	–	90,000	–	1.64%	–
DERM	Sell	Dermira, Inc.	$1,583,000	-59.8%	58,624	-56.7%	0.64%	-64.5%
LOXO	New	Loxo Oncology, Inc.	$1,317,000	–	14,300	–	0.53%	–
OREXQ	Sell	Orexigen Therapeutics, Inc.	$1,109,000	-36.5%	523,132	-13.1%	0.45%	-43.8%
ZFGN	Sell	Zafgen, Inc.	$108,000	-74.3%	30,775	-74.3%	0.04%	-77.1%
ARDX	Exit	Ardelyx, Inc.	$0	–	-37,500	–	-0.09%	–
SGMO	Exit	Sangamo Therapeutics, Inc.	$0	–	-46,000	–	-0.19%	–
BLCM	Exit	Bellicum Pharmaceuticals, Inc.	$0	–	-50,559	–	-0.27%	–
AKBA	Exit	Akebia Therapeutics Inc.	$0	–	-50,000	–	-0.33%	–
NSTG	Exit	NanoString Technologies, Inc.	$0	–	-254,015	–	-1.92%	–

Q2 2017

			Value		Shares		↓ Weighting
AERI	New	Aerie Pharmaceuticals, Inc.	$87,901,000	–	1,672,714	–	40.27%	–
AIMT	New	Aimmune Therapeutics, Inc.	$82,086,000	–	3,992,517	–	37.61%	–
EPZM	New	Epizyme, Inc.	$22,420,000	–	1,484,740	–	10.27%	–
ALDR	New	Alder BioPharmaceuticals, Inc.	$11,952,000	–	1,043,832	–	5.48%	–
NSTG	New	NanoString Technologies, Inc.	$4,201,000	–	254,015	–	1.92%	–
DERM	New	Dermira, Inc.	$3,942,000	–	135,294	–	1.81%	–
OREXQ	New	Orexigen Therapeutics, Inc.	$1,746,000	–	602,013	–	0.80%	–
JNCE	New	Jounce Therapeutics, Inc.	$1,682,000	–	119,912	–	0.77%	–
AKBA	New	Akebia Therapeutics Inc.	$719,000	–	50,000	–	0.33%	–
BLCM	New	Bellicum Pharmaceuticals, Inc.	$591,000	–	50,559	–	0.27%	–
ZFGN	New	Zafgen, Inc.	$420,000	–	119,695	–	0.19%	–
SGMO	New	Sangamo Therapeutics, Inc.	$405,000	–	46,000	–	0.19%	–
ARDX	New	Ardelyx, Inc.	$191,000	–	37,500	–	0.09%	–

Q4 2016

			Value		Shares		↓ Weighting
BDSI	Exit	BioDelivery Sciences International, Inc.	$0	–	-225,281	–	-0.29%	–
OREX	Exit	Orexigen Therapeutics, Inc.	$0	–	-542,755	–	-0.86%	–
ZFGN	Exit	Zafgen, Inc.	$0	–	-760,046	–	-1.20%	–
NVET	Exit	Nexvet Biopharma public limited company	$0	–	-900,155	–	-1.78%	–
NSTG	Exit	NanoString Technologies, Inc.	$0	–	-752,857	–	-7.18%	–
EPZM	Exit	Epizyme, Inc.	$0	–	-1,543,118	–	-7.25%	–
UAM	Exit	Universal American Corp.	$0	–	-2,820,791	–	-10.30%	–
ALDR	Exit	Alder Biopharmaceuticals Inc.	$0	–	-802,724	–	-12.56%	–
AIMT	Exit	Aimmune Therapeutics, Inc.	$0	–	-3,967,900	–	-28.42%	–
AERI	Exit	Aerie Pharmaceuticals, Inc.	$0	–	-1,672,714	–	-30.14%	–

Q3 2016

			Value		Shares		↓ Weighting
AERI	Buy	Aerie Pharmaceuticals, Inc.	$63,128,000	+267.8%	1,672,714	+71.5%	30.14%	+156.9%
ALDR	Buy	Alder Biopharmaceuticals Inc.	$26,305,000	+75.3%	802,724	+33.6%	12.56%	+22.5%
UAM	Buy	Universal American Corp.	$21,579,000	+1.1%	2,820,791	+0.2%	10.30%	-29.4%
EPZM	Buy	Epizyme, Inc.	$15,184,000	+24.4%	1,543,118	+29.5%	7.25%	-13.1%
NSTG	Buy	NanoString Technologies, Inc.	$15,042,000	+64.0%	752,857	+3.4%	7.18%	+14.6%
OREX	Sell	Orexigen Therapeutics, Inc.	$1,802,000	-22.8%	542,755	-90.0%	0.86%	-46.1%
BDSI	Sell	BioDelivery Sciences International, Inc.	$608,000	-23.1%	225,281	-32.8%	0.29%	-46.4%
RGNX	Exit	Regenxbio Inc.	$0	–	-156,741	–	-0.86%	–
	Exit	NeuroDerm Ltd.	$0	–	-83,211	–	-0.92%	–
XLRN	Exit	Acceleron Pharma Inc.	$0	–	-48,839	–	-1.14%	–
ARDX	Exit	Ardelyx, Inc.	$0	–	-428,989	–	-2.56%	–
ADAP	Exit	Adaptimmune Therapeutics plcsponsored adr	$0	–	-1,054,864	–	-5.88%	–

Q2 2016

			Value		Shares		↓ Weighting
AIMT	New	Aimmune Therapeutics, Inc.	$42,933,000	–	3,967,900	–	29.35%	–
UAM	New	Universal American Corp.	$21,337,000	–	2,814,883	–	14.59%	–
AERI	New	Aerie Pharmaceuticals, Inc.	$17,165,000	–	975,285	–	11.73%	–
ALDR	New	Alder Biopharmaceuticals Inc.	$15,005,000	–	600,929	–	10.26%	–
EPZM	New	Epizyme, Inc.	$12,206,000	–	1,191,995	–	8.34%	–
NSTG	New	NanoString Technologies, Inc.	$9,171,000	–	727,857	–	6.27%	–
ADAP	New	Adaptimmune Therapeutics plcsponsored adr	$8,597,000	–	1,054,864	–	5.88%	–
ZFGN	New	Zafgen, Inc.	$4,553,000	–	760,046	–	3.11%	–
NVET	New	Nexvet Biopharma public limited company	$4,177,000	–	900,155	–	2.86%	–
ARDX	New	Ardelyx, Inc.	$3,745,000	–	428,989	–	2.56%	–
OREX	New	Orexigen Therapeutics, Inc.	$2,334,000	–	5,427,559	–	1.60%	–
XLRN	New	Acceleron Pharma Inc.	$1,660,000	–	48,839	–	1.14%	–
	New	NeuroDerm Ltd.	$1,352,000	–	83,211	–	0.92%	–
RGNX	New	Regenxbio Inc.	$1,254,000	–	156,741	–	0.86%	–
BDSI	New	BioDelivery Sciences International, Inc.	$791,000	–	335,239	–	0.54%	–

Q4 2015

			Value		Shares		↓ Weighting
OREX	Exit	Orexigen Therapeutics, Inc.call	$0	–	-85,000	–	-0.05%	–
AXGT	Exit	Axovant Sciences Ltd.	$0	–	-65,000	–	-0.26%	–
BITI	Exit	Biotie Therapies Corp.sponsored adr	$0	–	-80,883	–	-0.32%	–
	Exit	NeuroDerm Ltd.	$0	–	-76,801	–	-0.48%	–
RGLS	Exit	Regulus Therapeutics Inc.put	$0	–	-250,000	–	-0.50%	–
RGLS	Exit	Regulus Therapeutics Inc.call	$0	–	-250,000	–	-0.50%	–
BDSI	Exit	BioDelivery Sciences International, Inc.call	$0	–	-310,000	–	-0.52%	–
BDSI	Exit	BioDelivery Sciences International, Inc.put	$0	–	-310,000	–	-0.52%	–
EPZM	Exit	Epizyme, Inc.put	$0	–	-150,000	–	-0.59%	–
SCYX	Exit	SCYNEXIS, Inc.	$0	–	-337,177	–	-0.74%	–
NVET	Exit	Nexvet Biopharma public limited company	$0	–	-708,332	–	-0.78%	–
RGNX	Exit	Regenxbio Inc.	$0	–	-156,741	–	-1.05%	–
	Exit	Anacor Pharmaceuticals, Inc.put	$0	–	-31,000	–	-1.11%	–
	Exit	Anacor Pharmaceuticals, Inc.call	$0	–	-31,000	–	-1.11%	–
QTNT	Exit	Quotient Limited	$0	–	-291,229	–	-1.15%	–
BDSI	Exit	BioDelivery Sciences International, Inc.	$0	–	-881,562	–	-1.49%	–
XLRN	Exit	Acceleron Pharma Inc.	$0	–	-198,717	–	-1.50%	–
NSTG	Exit	NanoString Technologies, Inc.	$0	–	-464,486	–	-2.26%	–
OREX	Exit	Orexigen Therapeutics, Inc.	$0	–	-4,225,047	–	-2.71%	–
	Exit	Ardelyx, Inc.	$0	–	-517,290	–	-2.71%	–
	Exit	Alder Biopharmaceuticals Inc.	$0	–	-344,770	–	-3.43%	–
RGLS	Exit	Regulus Therapeutics Inc.	$0	–	-1,750,269	–	-3.48%	–
EPZM	Exit	Epizyme, Inc.	$0	–	-1,009,795	–	-3.94%	–
AERI	Exit	Aerie Pharmaceuticals, Inc.	$0	–	-906,317	–	-4.88%	–
UAM	Exit	Universal American Corp.	$0	–	-2,814,883	–	-5.85%	–
ADAP	Exit	Adaptimmune Therapeutics plcsponsored adr	$0	–	-1,757,268	–	-6.39%	–
ZFGN	Exit	Zafgen, Inc.	$0	–	-811,300	–	-7.87%	–
ADRO	Exit	Aduro Biotech, Inc.	$0	–	-2,106,734	–	-12.39%	–
AIMT	Exit	Aimmune Therapeutics, Inc.	$0	–	-4,087,900	–	-31.43%	–

Q3 2015

			Value		Shares		↓ Weighting
AIMT	New	Aimmune Therapeutics, Inc.	$103,506,000	–	4,087,900	–	31.43%	–
AERI	Buy	Aerie Pharmaceuticals, Inc.	$16,078,000	+13.1%	906,317	+12.6%	4.88%	-2.1%
EPZM	Buy	Epizyme, Inc.	$12,986,000	-39.7%	1,009,795	+12.5%	3.94%	-47.9%
RGLS	Buy	Regulus Therapeutics Inc.	$11,447,000	+16.9%	1,750,269	+95.8%	3.48%	+1.1%
OREX	Buy	Orexigen Therapeutics, Inc.	$8,915,000	-57.1%	4,225,047	+0.6%	2.71%	-62.9%
XLRN	Buy	Acceleron Pharma Inc.	$4,948,000	+402.8%	198,717	+539.0%	1.50%	+335.4%
BDSI	Buy	BioDelivery Sciences International, Inc.	$4,901,000	-13.6%	881,562	+23.8%	1.49%	-25.2%
QTNT	Sell	Quotient Limited	$3,786,000	-14.2%	291,229	-2.4%	1.15%	-25.8%
	New	Anacor Pharmaceuticals, Inc.call	$3,649,000	–	31,000	–	1.11%	–
	New	Anacor Pharmaceuticals, Inc.put	$3,649,000	–	31,000	–	1.11%	–
RGNX	New	Regenxbio Inc.	$3,453,000	–	156,741	–	1.05%	–
SCYX	Sell	SCYNEXIS, Inc.	$2,455,000	-55.5%	337,177	-46.3%	0.74%	-61.5%
EPZM	New	Epizyme, Inc.put	$1,929,000	–	150,000	–	0.59%	–
BDSI	New	BioDelivery Sciences International, Inc.call	$1,724,000	–	310,000	–	0.52%	–
BDSI	New	BioDelivery Sciences International, Inc.put	$1,724,000	–	310,000	–	0.52%	–
RGLS	New	Regulus Therapeutics Inc.call	$1,635,000	–	250,000	–	0.50%	–
RGLS	New	Regulus Therapeutics Inc.put	$1,635,000	–	250,000	–	0.50%	–
	Buy	NeuroDerm Ltd.	$1,587,000	+39.0%	76,801	+3.2%	0.48%	+20.2%
BITI	Sell	Biotie Therapies Corp.sponsored adr	$1,059,000	-71.9%	80,883	-57.2%	0.32%	-75.7%
OREX	Sell	Orexigen Therapeutics, Inc.call	$179,000	-69.9%	85,000	-29.2%	0.05%	-74.0%
AGRX	Exit	Agile Therapeutics, Inc.	$0	–	-49,870	–	-0.15%	–
JUNO	Exit	Juno Therapeutics Inc.	$0	–	-91,575	–	-1.71%	–

Q2 2015

			Value		Shares		↓ Weighting
ADRO	New	Aduro Biotech, Inc.	$63,897,000	–	2,106,734	–	22.42%	–
ADAP	New	Adaptimmune Therapeutics plcsponsored adr	$32,211,000	–	1,757,268	–	11.30%	–
UAM	New	Universal American Corp.	$28,487,000	–	2,814,883	–	10.00%	–
ZFGN	New	Zafgen, Inc.	$28,095,000	–	811,300	–	9.86%	–
EPZM	New	Epizyme, Inc.	$21,549,000	–	897,863	–	7.56%	–
OREX	New	Orexigen Therapeutics, Inc.	$20,790,000	–	4,200,047	–	7.30%	–
	New	Alder Biopharmaceuticals Inc.	$18,262,000	–	344,770	–	6.41%	–
AERI	New	Aerie Pharmaceuticals, Inc.	$14,212,000	–	805,217	–	4.99%	–
RGLS	New	Regulus Therapeutics Inc.	$9,796,000	–	893,781	–	3.44%	–
	New	Ardelyx, Inc.	$8,261,000	–	517,290	–	2.90%	–
NSTG	New	NanoString Technologies, Inc.	$7,162,000	–	464,486	–	2.51%	–
BDSI	New	BioDelivery Sciences International, Inc.	$5,670,000	–	712,278	–	1.99%	–
SCYX	New	SCYNEXIS, Inc.	$5,521,000	–	628,155	–	1.94%	–
JUNO	New	Juno Therapeutics Inc.	$4,884,000	–	91,575	–	1.71%	–
QTNT	New	Quotient Limited	$4,413,000	–	298,360	–	1.55%	–
BITI	New	Biotie Therapies Corp.sponsored adr	$3,772,000	–	188,900	–	1.32%	–
NVET	New	Nexvet Biopharma public limited company	$3,520,000	–	708,332	–	1.24%	–
AXGT	New	Axovant Sciences Ltd.	$1,325,000	–	65,000	–	0.46%	–
	New	NeuroDerm Ltd.	$1,142,000	–	74,385	–	0.40%	–
XLRN	New	Acceleron Pharma Inc.	$984,000	–	31,100	–	0.34%	–
OREX	New	Orexigen Therapeutics, Inc.call	$594,000	–	120,000	–	0.21%	–
AGRX	New	Agile Therapeutics, Inc.	$428,000	–	49,870	–	0.15%	–

Compare quarters

Export Foresite Capital Management II, LLC's holdings